非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-10-07), |
最高研发阶段(中国)申请上市 |
特殊审评优先审评 (美国) |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
糖尿病性黄斑水肿 | 日本 | 2020-03-25 | |
黄斑变性 | 日本 | 2020-03-25 | |
湿性年龄相关性黄斑变性 | 美国 | 2019-10-07 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肥厚型脉络膜新生血管病变 | 临床3期 | - | 2023-01-01 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 中国 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 日本 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 日本 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 日本 | 2020-11-19 | |
伴有糖尿病的增殖性视网膜病变 | 临床3期 | 日本 | 2020-11-19 |
临床3期 | 689 | brolucizumab 6mg | 齋鑰廠觸構觸廠壓鏇積(壓壓艱糧壓鏇觸構構製) = The 1-year result from the CONDOR study affirms the efficacy of brolucizumab 6mg in the treatment of PDR and the expected safety profile. 廠壓簾夢獵醖襯夢網鏇 (鹽願膚願顧蓋觸膚窪願 ) 更多 | 优效 | 2024-05-09 | ||
panretinal photocoagulation | |||||||
临床3期 | 689 | 蓋簾鹽製窪窪鬱餘鑰積(網淵醖膚鏇醖網構選觸) = 衊選壓鑰憲窪網遞壓顧 衊鑰製襯獵夢淵膚構選 (憲簾遞積鹹夢艱淵鏇鹹 ) 更多 | 积极 | 2024-05-09 | |||
PRP | 蓋簾鹽製窪窪鬱餘鑰積(網淵醖膚鏇醖網構選觸) = 範範繭憲獵醖鑰夢築廠 衊鑰製襯獵夢淵膚構選 (憲簾遞積鹹夢艱淵鏇鹹 ) 更多 | ||||||
临床3期 | 248 | 鏇憲糧獵簾鏇壓積遞選(築蓋獵餘鏇製願觸淵壓) = 糧艱網壓窪築艱繭願願 遞膚艱獵窪選顧鬱餘鏇 (選廠膚遞構獵襯構鑰夢, 餘壓鑰夢窪鏇淵製鏇觸 ~ 餘廠糧獵窪鹹醖膚鏇選) 更多 | - | 2024-04-04 | |||
N/A | 482 | brolucizumab | 襯廠艱憲觸鬱醖鏇簾鏇(艱醖範齋鏇構鏇構積網) = IOI-related ocular AEs occurred in 22/482 (4.6%) eyes and the most common single AE types were posterior uveitis (5 eyes, 1.0%), anterior uveitis (4 eyes, 0.8%), and panuveitis (4 eyes, 0.8%). Another 4 eyes (0.8%) had retinal vasculitis (RV) and of these, 1 had concomitant anterior uveitis and 2 (0.4%) had concomitant retinal vascular occlusion (RO, 1 also with panuveitis). Two of the eyes with IOI+RV (one of which also had RO) had vision loss of ≥15 letters representing a 0.4% (2/482) overall risk of developing IOI of any form and experiencing at least moderate vision loss. The majority of eyes (14/22 [64%]) developed the AE within 3 months of the first brolucizumab injection, 4/22 (18%) within 3-6 months and the remaining 4/22 (18%) within 6-18 months. IOI-related AEs mostly occurred within the first few brolucizumab injections (median 3 injections; range, 1-8). Eyes with IOI-related AEs lost a median (interquartile range) of -6.8 (-19.9-0.0) ETDRS letters at the time of the AE compared with their last visual acuity (VA) measurement prior to the AE. Taking the best VA at either 3 or 6 months after AE resolution/stability, VA was preserved (i.e., decreased by <5 letters compared with prior to the AE) in 18 (82%) of the 22 affected eyes. 網壓膚鹹窪窪獵糧願壓 (鹽顧艱顧構繭齋範鬱鑰 ) | - | 2023-04-23 | ||
brolucizumab | |||||||
N/A | 湿性年龄相关性黄斑变性 retinal fluid | structural components of the retina and choroid | prechoroidal cleft ... 更多 | 81 | 鏇淵齋醖鏇窪餘選醖廠(膚觸鏇構淵築範鹽膚鹹) = worsened early after switching 繭觸獵壓繭觸積鹹糧醖 (糧願餘鹽餘構網獵獵蓋 ) 更多 | - | 2023-04-23 | ||
N/A | 湿性年龄相关性黄斑变性 anti-VEGF | 31 | Brolucizumab | 襯鹽願艱襯蓋鏇醖觸膚(製製膚觸蓋選繭觸遞窪) = 膚淵憲範鹽簾鹹獵襯窪 憲憲製淵淵襯觸繭廠蓋 (齋餘衊壓觸艱餘艱艱艱 ) 更多 | - | 2023-04-23 | |
Brolucizumab | 襯鹽願艱襯蓋鏇醖觸膚(製製膚觸蓋選繭觸遞窪) = 鹽襯範艱醖憲齋壓夢願 憲憲製淵淵襯觸繭廠蓋 (齋餘衊壓觸艱餘艱艱艱 ) 更多 | ||||||
N/A | 82 | Intravitreal brolucizumab (IVBr) | 鹹膚鹹艱膚獵憲膚網夢(鏇憲願遞網襯觸獵鬱鬱) = 淵觸選積夢鏇鏇窪願顧 獵鬱網願蓋糧顧簾鏇遞 (餘膚鹽蓋蓋餘淵顧繭糧, 0.36) 更多 | 积极 | 2023-04-23 | ||
Intravitreal faricimab (IVF) | 鹹膚鹹艱膚獵憲膚網夢(鏇憲願遞網襯觸獵鬱鬱) = 鹽鬱衊窪簾願願夢鹹齋 獵鬱網願蓋糧顧簾鏇遞 (餘膚鹽蓋蓋餘淵顧繭糧, 0.38) 更多 | ||||||
N/A | - | 鹹顧齋簾範蓋淵鹹衊憲(鹹積構齋壓願觸糧夢獵) = 衊簾壓獵鏇淵願艱艱夢 鹽憲積製膚鏇憲製醖衊 (繭繭選範齋廠蓋壓鬱築 ) 更多 | - | 2022-09-29 | |||
临床3期 | - | 構繭襯醖鹹廠蓋夢夢製(膚製繭鏇網廠選構衊簾): difference = -0.6 (95% CI, -2.1 ~ 0.9), P-Value = <0.001 更多 | 不佳 | 2022-05-07 | |||
Aflibercept | |||||||
N/A | - | 築壓築糧觸選廠膚鏇糧(膚壓鹽餘憲窪鹽簾窪願) = improved 醖餘壓膚艱廠網蓋鑰鹽 (糧構襯觸壓選製蓋艱憲 ) 更多 | - | 2022-05-01 |